Seroprevalence of hepatitis A immunity among Brazilian adult patients with liver cirrhosis: is HAV vaccination necessary?

de Oliveira, Luiz Carlos Marques; Comácio, Samantha Martins; Gonçalves Santos, Júlia de Fátima

doi:10.1016/S1413-8670(11)70187-8

Article information

Abstract

Background

Patients with chronic liver disease have a higher risk of fulminant hepatitis when infected with hepatitis A virus, and vaccination of these patients against such infection is recommended. In Brazil, mainly in the South and Southeast regions, the epidemiology of hepatitis A (HA) has shifted from high to intermediate endemicity, which would have implication on policy of HA vaccination for these populations.

Objective

To verify the prevalence of HA immunity in adult patients with liver cirrhosis (LC), in Uberlândia MG, a city of Southeastern Brazil.

Methods

Between December 2005 and December 2006, 106 patients with LC were consecutively evaluated. In addition, 75 individuals without LC or alcoholism were evaluated (control group - CG).

Results

Total anti-HAV (ELISA methods) was positive in 104 (98.1%) patients with LC (82 men, 24 women; mean age, 53.3±11.9 years) and in 74 (98.7%) individuals of the CG (55 men, 20 women; mean age, 47±11.6 years), p>0.05.

Conclusions

For patients with chronic liver disease, in the geographic regions and age groups evaluated, routine vaccination against hepatitis A is not recommended. Moreover, the serum determination of total anti-HAV, used to assess immunity, is five times cheaper than vaccination against hepatitis A and, for this reason, should precede vaccination.

Keywords:

hepatitis A vaccines

hepatitis A virus

liver cirrhosis

prevalence

Full text is only aviable in PDF

References

[1.]

Prevention of hepatitis A. through active or passive immunization.

Recommendations of the advisory committee on immunization practices (ACIP).

MMWR Recomm Rep, 48 (1999), pp. 1-37

Medline

[2.]

R.S. Koff, A. Hepatitis.

Lancet, 351 (1998), pp. 1643-1649

http://dx.doi.org/10.1016/S0140-6736(98)01304-X | Medline

[3.]

N.G. Barzaga.

Hepatitis A shifting epidemiology in South-East Asia and China.

Vaccine, 18 (2000), pp. S61-S64

Medline

[4.]

S.A.C. Clemens, J.C. Fonseca, T. Azevedo, et al.

Soroprevalência para hepatite A e hepatite B em quatro centros no Brasil.

Rev Soc Bras Med Trop, 33 (2000), pp. 1-10

Medline

[5.]

C.L. Vitral, C.F.T. Yoshida, E.R.S. Lemos, C.S. Teixeira, A.M.C. Gaspar.

Age-specific prevalence of antibodies to hepatitis A in children and adolescents from Rio de Janeiro, Brazil, 1978 and 1995. Relationship of prevalence to environmental factors.

Mem Inst Oswaldo Cruz, 93 (1998), pp. 1-5

Medline

[6.]

M.P. Zago-Gomes, G.C. Stantolin, S. Perazzio, K.H. Aikawa, C.S. Gonçalves, F.E.L. Pereira.

Prevalence of anti-hepatitis A antibodies in children of different socioeconomic conditions in Vila Velha, ES.

Rev Soc Bras Med Trop, 38 (2005), pp. 285-289

http://dx.doi.org//S0037-86822005000400001 | Medline

[7.]

M.I.S. Dinelli, M. Fisberg, M.I. Moraes-Pinto.

Anti-hepatitis A virus frequency in adolescents at an outpatient clinic in São Paulo, Brazil.

Rev Inst Med Trop S. Paulo, 48 (2006), pp. 43-44

http://dx.doi.org//S0036-46652006000100009 | Medline

[8.]

E.B. Keeffe.

Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?.

Am J Gastroenterol, 90 (1995), pp. 201-205

Medline

[9.]

G. Reiss, E.B. Keeffe.

Review article: hepatitis vaccination in patients with chronic liver disease.

Aliment Pharmacol Ther, 19 (2004), pp. 715-727

http://dx.doi.org/10.1111/j.1365-2036.2004.01906.x | Medline

[10.]

S. Vento, T. Garofano, C. Renzini, et al.

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.

N Engl J Med, 338 (1998), pp. 286-290

http://dx.doi.org/10.1056/NEJM199801293380503 | Medline

[11.]

E.A. Akriviadis, A.G. Redeker.

Fulminant hepatitis A in intravenous drug users with chronic liver disease.

Ann Intern Med, 110 (1989), pp. 838-839

Medline

[12.]

L.C.M. Oliveira, A.G. Buso, A.T. Oliveira, C.A. Arantes, L.V. Borges, S.R.G. Valente.

Prevalence of hepatitis B and hepatitis C markers in alcoholics with and without clinically evident hepatic cirrhosis.

Rev Inst Med Trop. São Paulo, 41 (1999), pp. 69-73

Medline

[13.]

J.A. Ewing.

Detecting alcoholism. The CAGE questionnaire.

JAMA, 252 (1984), pp. 1905-1907

Medline

[14.]

J.Y. Wang, S.D. Lee, Y.T. Tsai, K.J. Lo, B.N. Chiang.

Fulminant hepatitis A in chronic HBV carrier (letter).

Dig Dis Sci, 31 (1986), pp. 109-111

Medline

[15.]

M.R. Arguedas, A. Johnson, M.A. Eloubeidi, M.B. Fallon.

Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients.

Hepatology, 34 (2001), pp. 28-31

http://dx.doi.org/10.1053/jhep.2001.25883 | Medline

[16.]

S.K. Acharya, Y. Batra, B. Bhatkal, et al.

Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination.

J Gastroenterol Hepatol, 18 (2003), pp. 822-827

Medline

[17.]

A. Duseja, S. Sharma, K. Das, R.K. Dhiman, Y.K. Chawla.

Is vaccination against hepatitis A virus required in patients with cirrhosis of the liver?.

Trop Gastroenterol, 25 (2004), pp. 162-163

Medline

[18.]

L.M. Villar, M.M.M. Melo, I.A. Calado, A.J. Almeida, E. Lampe, A.M.C. Gaspar.

Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?.

J Gastroenterol Hepatol, 24 (2009), pp. 238-242

http://dx.doi.org/10.1111/j.1440-1746.2008.05575.x | Medline